IG
ALNY icon

ING Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

ING Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$426K Sell
1,289
-1,155
-47% -$393K ﹤0.01% 473
2025
Q4 		$972K Buy
+2,444
New +$1.08M 0.01% 478
2014
Q2 		– Sell
-10,949
Closed -$735K – 642
2014
Q1 		$735K Buy
+10,949
New +$848K ﹤0.01% 590

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ING Group's ALNY Position: Q1 2026 in Review

ING Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 47% in Q1 2026, selling an estimated $393K and leaving 1,289 shares worth $426K. The position accounts for ﹤0.01% of the portfolio, ranked #473.

ING Group first reported a position in ALNY in Q1 2014 and has held it in 3 quarters since. The position peaked at $972K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • ING Group held 1,289 shares of Alnylam Pharmaceuticals worth $426K as of Q1 2026.
  • ING Group sold 1,155 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $393K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of ING Group's portfolio in Q1 2026, its #473 holding.
  • ING Group first reported a position in Alnylam Pharmaceuticals in Q1 2014 and has held it in 3 quarters since.
  • ING Group's Alnylam Pharmaceuticals position peaked at $972K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on ING Group's 13F filing for Q1 2026, filed 11 May 2026.